EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Tirzepatide-Induced Injection Site Reaction

Junki Mizumoto

Cureus · 13.09.2023

DOI: 10.7759/cureus.45181 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cureus, erschienen am 13.09.2023. Verfasst von Junki Mizumoto. Beteiligte Einrichtung: Department of Medical Education Studies, International Research Center for Medical Education, Graduate School of Medicine, The University of Tokyo, T…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide. The rash diminished after stopping tirzepatide injection. This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being used without adverse reactions. Injection site reactions are one of the potential adverse events associated with GLP-1 RA use. To the best of our knowledge, this is the first reported case of tirzepatide-induced injection site reaction.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reactiondiabetes mellitusglucagon-like peptide-1 receptor agonistrashtirzepatide

Autor:innen und Institutionen

  • Department of Medical Education Studies, International Research Center for Medical Education, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.

Zitieren

APA

Mizumoto, J. (2023). Tirzepatide-Induced Injection Site Reaction. Cureus. https://doi.org/10.7759/cureus.45181

Vancouver

Mizumoto J. Tirzepatide-Induced Injection Site Reaction. Cureus. 2023. doi:10.7759/cureus.45181

BibTeX
@article{Mizumoto2023,
  author = {Mizumoto, Junki},
  title = {Tirzepatide-Induced Injection Site Reaction},
  journal = {Cureus},
  year = {2023},
  doi = {10.7759/cureus.45181}
}
Kostenlos starten →